M.K. Sethi et al. / Journal of Molecular Catalysis B: Enzymatic 91 (2013) 87–92
91
100
Acknowledgments
90
80
70
60
50
40
30
20
10
0
Our group thanks Department of Scientific and Industrial
Research India, Dr. Hari Babu (CEO Mylan Laboratories Ltd., India);
Mr. Sanjeev Sethi (Head Mylan Global R & D); Dr. Ramesh Dandala
(Head MLL R & D); Dr. Abhay Gaitonde (Head Manufacturing MLL);
Dr. Suryanarayana Mulukutla (Head Analytical Dept. MLL R & D) as
well as analytical development team of Mylan Laboratories Ltd. for
their encouragement and support. We will also like to thanks Dr.
Narahari Ambati (Head IPR MLL R & D) & his Intellectual property
team for their support.
References
25
30
35
40
Temperature (Degree Celcius)
[
[
1] R. Polinsky, J. Clin. Ther. 20 (1998) 634–647.
2] M. Rosler, R. Anand, A. Cicin-Sain, S. Gauthier, Y. Agid, H.B. Dal-P-
Bianco, R. Stahelin, Hartman, M. Gharabawi, Br. Med. J. 318 (1999)
Fig. 2. Effect of temperature. % conversion from HPLC determined with respect
to (1). 0.0045 mol of (1), 2 g baker’s yeast, 4 mL toluene, 6 mL of EDTA.2Na, 13 mL
of 0.25 M phosphate buffer, 0.1 g NAD, 5 g d-glucose, 0.1 g glucose dehydrogenase
CDX901, 3 mL DMSO, with shaking for 24 h.
633–638.
[3] P.J. Reading, A.K. Luce, I.G. McKeith, Mov. Disord. 16 (2001) 1171–1174.
[4] I. McKeith, T. Del Ser, P. Spano, M. Emre, K. Wesnes, R. Anand, A. Cicin-Sain, R.
Ferrara, R. Spiegel, Lancet 356 (2000) 2031–2036.
[
[
[
5] J. Ogorka, O. Kalb, R. Shah, S.C. Khanna, United States Patent 6,565,883 (2003).
6] W. Chen, F. Wen, China Patent 200710030658 (2008).
7] A.A. Boezio, J. Pytkowicz, A. Cote, A.B. Charette, J. Am. Chem. Soc. 125 (2003)
100
14260–14261.
[
[
8] M. Hu, F.-L. Zhang, M.-H. Xie, Synth. Commun. 39 (2009) 1527–1533.
9] N. Stepankova, J. Hajicek, European Patent 1556338 (2008).
7
5
2
5
0
5
0
[10] V. Bansal, S.K. Dubey, S.K. Dubey, K. Pannu, European Patent 2349976
2011).
11] C.B.H. Stepankova, P.J. Hajicek, P. Simek, United States Patent 20,060,122,417
2009).
12] G. Tian, Y. Zhu, J. Shen, World Intellectual Property Organization Patent
008124969 (2008).
(
[
[
[
(
2
13] V.N.B.R. Mandava, V.R. Vajrala, G. Varanasi, V.K. Adla, M.R. Jambula, V.R.K.
Reddy, United States Patent 20,080,255,383 (2008).
[
[
14] H.V. Patel, United States Patent 20,060,293,518 (2006).
15] M.S.M. Jaweed, B.K. Upadhye, V.K. Rai, H. Zia, World Intellectual Property Orga-
nization Patent 2007026373 (2007).
[16] P.B. Deshpande, B.B. Boda, H.H. Acharya, P.K. Luthra, United States Patent
0,080,045,743 (2008).
2
2.5
3.5
4.5
5.5
[
17] P.B. Deshpande, K. Khemani, B.B. Boda, T.R. Shah, H.H. Acharya, P.K. Luthra,
United States Patent 7,683,205 (2010).
Substrate Concentration in mmole
[
18] P.B. Deshpande, K. Khemani, B.B. Boda, T.R. Shah, H.H. Acharya, P.K.
Luthra, World Intellectual Property Organization Patent 2005020452
Fig. 3. Effect of substrate concentration. % conversion from HPLC determined with
respect to (1). 2 g baker’s yeast, 4 mL toluene, 6 mL of EDTA.2Na, 13 mL of 0.25 M
phosphate buffer, 0.1 g NAD, 5 g d-glucose, 0.1 g glucose dehydrogenase CDX901,
(
2005).
[19] J. Mangas-Sanchez, Rodrıguez-Mata, E. Busto, V. Gotor-Fernandez, V.J. Gotor,
Org. Chem. 74 (2009) 5304–5310.
3
mL DMSO, with shaking for 24 h.
[20] K. Han, C. Kim, J. Park, M.-J. Kim, J. Org. Chem. 75 (2010) 3105–3108.
[
[
[
21] K. Arunkumar, M.A. Reddy, T.S. Kumar, B.V. Kumar, K.B. Chandrasekhar, P.R.
Kumar, M. Pal, Beilstein J. Org. Chem. 6 (2010) 1174–1179.
22] M. Fuchs, D. Koszelewski, K. Tauber, W. Kroutil, K. Faber, Chem. Commun. 46
3
.9. Effect of substrate concentration
(
2010) 5500–5502.
23] M.K. Sethi, S.R. Bhandya, N. Maddur, S. Potluri, D. Dutta, R. Dandala, India Patent
Office 2681/CHE/2010 (2012).
A maximum conversion of 99.2 has been obtained at 0.035 mol
of N-ethyl-N-methyl carbomyl acetophenone (1) when cell free
extract from baker’s yeast at concentrations ranging from 2.5 to
[24] W.J. Rutter, J.R. Hunsley, in: W.A. Wood (Ed.), Methods in Enzymology, vol. 9,
Academic Press, New York, 1966, pp. 480–486.
[
25] S.C. Davis, J.H. Grate, D.R. Gray, J.H. Gruber, G.W. Huisman, S.K. Ma,
L.M. Newman, R. Sheldon, L.A. Wang, United States Patent 7,132,267
(2006).
4
.5 mmol of N-ethyl-N-methyl carbomyl acetophenone (1), 0.1 of g
NAD, 0.1 g of glucose dehydrogenase CDX901 with incubation upto
[
26] S.C. Davis, J.H. Grate, R.G. David, J.M. Gruber, G.W. Huisman, S.K. Ma, L.M. New-
man, United States Patent 7,125,693 (2006).
2
4 h were used (Fig. 3).
[
27] H. Werner, R. Bettina, H. Werner, R. Bettina, United States Patent 6,413,750
(
2002).
4
. Conclusion
[
28] C-H. Wong, C.W. Bradshaw, United States Patent 5,225,339 (1992).
29] R.N. Patel, A. Banerjee, C.G. McNamee, L.J. Szarka, United States Patent 5,391,495
(1995).
[
The above process is first of its kind. N-Ethyl-N-methyl carbomyl
[
30] J.C. Moore, M.G. Sturr, K. McLaughlin, J. Kim, United States Patent 7,109,004
acetophenone (1) synthesized by condensation of N-ethyl-N-
methyl carbomyl chloride with 3-hydroxy acetophenone has been
screened for stereoselective reduction by enzyme alcohol dehydro-
genase, NAD/NADP, glucose and glucose dehydrogenase of which
all alcohol dehydrogenases yielded best result with a ee purity of
(
2006).
[
31] N.D. Valerie, Process for preparing an intermediate of Sitagliptin via enzy-
matic reduction. World Intellectual Property Organization 2009045507
(
2009).
[
[
32] E. Keinan, S.C. Sinha, A. Sinha-Bagchi, J. Org. Chem. 57 (1992) 3631–3636.
33] R.N. Patel, L. Chu, R. Mueller, Tetrahedron: Asym. 14 (2003) 3105–3109.
9
8.5%. Glucose dehydrogenase CDX901 in presence of d-glucose
[34] B.N. Zhou, A.S. Gopalan, F. VanMiddlesworth, W.R. Shieh, J. Charles, C.J. Sih, J.
Am. Chem. Soc. 105 (1983) 5925–5926.
and NAD were used for regeneration of co-factor. Cell free extract
of Yeast taken for optimization showed with 10% of NADP, 10% glu-
cose dehydrogenase CDX901, 6.15 mol equivalent of d-glucose with
respect to N-ethyl-N-methyl carbomyl acetophenone (1) in 3 vol-
ume of dimethyl sulfoxide can able to reduce stereoselectively to
S-alcohol (2) with a yield of 95% with enantiomeric excess >99.0.
[
35] H. Gröger, W. Hummel, S. Buchholz, K. Drauz, T.V. Nguyen, C. Rollmann, H.
Hüsken, K. Abokitse, Org. Lett. 5 (2003) 173–176.
[36] M.D. Truppo, D. Pollard, P. Devine, Org. Lett. 9 (2007) 335–338.
[37] M.J. Kim, Y.S. Ahn, J.W. Park, Curr. Opin. Biotechnol. 13 (2002) 578–587.
[
38] O. Pamies, J.-E. Beackvall, Chem. Rev. 103 (2003) 3247–3261.
[
39] M.-J. Kim, J. Park, Y. Ahn, in: R.N. Patel (Ed.), Biocatalysis in the Pharmaceutical
and Biotechnology Industries, CRC Press, Boca Raton, 2007, pp. 249–272.